Bicocca Open Archive

Logo unimib boa
FONTANA, DILETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.741
EU - Europa 1.784
AS - Asia 452
SA - Sud America 18
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 2
Totale 5.002
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.698
IT - Italia 609
DE - Germania 448
IE - Irlanda 271
SE - Svezia 204
CN - Cina 203
HK - Hong Kong 97
GB - Regno Unito 74
UA - Ucraina 41
VN - Vietnam 35
CA - Canada 33
FI - Finlandia 29
IN - India 28
TR - Turchia 25
IQ - Iraq 23
FR - Francia 22
DK - Danimarca 21
SG - Singapore 18
BE - Belgio 15
RU - Federazione Russa 14
MX - Messico 10
AT - Austria 9
JP - Giappone 9
IR - Iran 8
CZ - Repubblica Ceca 7
EC - Ecuador 6
EU - Europa 5
PL - Polonia 5
BR - Brasile 4
PE - Perù 4
ID - Indonesia 3
NO - Norvegia 3
RO - Romania 3
AR - Argentina 2
BG - Bulgaria 2
CO - Colombia 2
ES - Italia 2
KR - Corea 2
NL - Olanda 2
AM - Armenia 1
CH - Svizzera 1
HU - Ungheria 1
MU - Mauritius 1
PT - Portogallo 1
SC - Seychelles 1
Totale 5.002
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.055
Frankfurt am Main 371
Dublin 268
Milan 230
Chandler 224
Wilmington 171
Fairfield 167
Ashburn 118
Houston 117
New York 98
Hong Kong 94
Dearborn 91
Woodbridge 84
Seattle 62
Princeton 56
Cambridge 45
Jacksonville 39
Shanghai 39
Beijing 37
Boyds 31
Altamura 30
Nanjing 28
Lawrence 26
Kirkuk 23
Dong Ket 21
Helsinki 21
Guangzhou 17
Boardman 15
Kocaeli 15
Brussels 14
Carate Brianza 14
Los Angeles 14
San Diego 14
Lissone 12
Pavia 12
Fremont 11
Meda 11
Monza 11
Andover 10
Ottawa 10
Sesto San Giovanni 10
Genoa 9
Munich 9
Nanchang 9
Pune 9
Vienna 9
Falls Church 8
Rome 8
Shenyang 8
Toronto 8
Lodi 7
Riva del Garda 7
Tianjin 7
Edmonton 6
Göttingen 6
Hebei 6
Jinan 6
Kunming 6
Washington 6
Bologna 5
Brno 5
Cinisello Balsamo 5
Cuenca 5
Hanoi 5
Lachine 5
London 5
Motta Di Livenza 5
Taku 5
Treviso 5
Cagliari 4
Cesena 4
Grafing 4
Hangzhou 4
Hounslow 4
Lodz 4
Marseille 4
Nova Milanese 4
Paris 4
Sacramento 4
Taizhou 4
Trento 4
Turin 4
Zanjan 4
Arese 3
Bonndorf 3
Boston 3
Colorado Springs 3
Jiaxing 3
Kiev 3
Kilburn 3
Lucino 3
Norwalk 3
Phoenix 3
Rawa Buaya 3
Redmond 3
Seriate 3
Taiyuan 3
Umeå 3
Acton 2
Agrate Brianza 2
Totale 4.025
Salva come PNG Salva come JPEG
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 367
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 289
Characterization of the role of mutated ETNK1 in the onset of atypical Chronic Myeloid Leukemia 284
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 271
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 259
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 245
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 229
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 214
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 186
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 185
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 177
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 173
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 169
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 167
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 163
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 162
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 149
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 139
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 139
Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage 133
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 130
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 117
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 109
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 107
Clonal evolution analysis identifies ETNK1 as an early event and SETBP1 as a late event in atypical Chronic Myeloid Leukemia 90
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 73
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 69
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 56
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 53
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 46
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 43
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia 42
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review 40
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 40
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 39
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 37
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 33
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 28
Role of somatic ETNK1 mutation in the mitochondrial activity 27
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 24
ETNK1 mutations increase mitochondrial activity and promote DNA damage through ROS production 21
Idiopathic erythrocytosis: a germline disease? 20
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 15
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape 12
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 5
Totale 5.376
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.469
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.469
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201977 0 0 0 0 0 0 0 0 0 0 36 41
2019/2020744 51 34 66 45 52 79 104 45 64 117 60 27
2020/20211.295 35 42 113 116 112 114 182 128 110 108 124 111
2021/2022651 84 88 79 61 36 59 21 20 30 43 56 74
2022/20231.152 108 271 124 104 110 152 18 62 64 34 32 73
2023/20241.063 46 43 64 76 122 276 235 36 105 52 8 0
Totale 5.376